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Background
Minimally differentiated acute myeloid leukemia is heterogeneous in karyotype and is
defined by immature morphological and molecular characteristics. This originally French-
American-British classification is still used in the new World Health Organization classifi-
cation when other criteria are not met. Apart from RUNX1 mutation, no characteristic
molecular aberrations are recognized.
Design and Methods
We performed whole genome single nucleotide polymorphism analysis and extensive
molecular analysis in a cohort of 52 patients with minimally differentiated acute myeloid
leukemia.
Results
Many recurring and potentially relevant regions of loss of heterozygosity were revealed.
These point towards a variety of candidate genes that could contribute to the pathogene-
sis of minimally differentiated acute myeloid leukemia, including the tumor suppressor
genes TP53 and NF1, and reinforced the importance of RUNX1 in this leukemia.
Furthermore, for the first time in this minimally differentiated form of leukemia we detect-
ed mutations in the transactivation domain of RUNX1. Mutations in other acute myeloid
leukemia associated transcriptions factors were infrequent. In contrast, FLT3, RAS, PTPN11
and JAK2 were often mutated. Irrespective of the RUNX1 mutation status, our results
show that RAS signaling is the most important pathway for proliferation in minimally dif-
ferentiated acute myeloid leukemia. Importantly, we found that high terminal deoxynu-
cleotidyl transferase expression is closely associated with RUNX1 mutation, which could
allow an easier diagnosis of RUNX1 mutation in this hematologic malignancy. 
Conclusions
Our results suggest that in patients without RUNX1 mutation, several other molecular
aberrations, separately or in combination, contribute to a common minimally differentiat-
ed phenotype.
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ABSTRACT
Introduction
Minimally differentiated acute myeloid leukemia
(AML-M0) is a distinct entity but heterogeneous in
manifestation.1 It accounts for less than 5% of all cases
of AML, is mostly seen in elderly patients and has a
remarkably poor prognosis.1-3 AML-M0 blasts show low
expression of myeloperoxidase, express at least one
myeloid surface antigen (CD13, CD33, CD15) and have
immunophenotypic characteristics of early progenitor
cells such as expression of CD34, terminal deoxynu-
cleotidyltransferase (TdT), HLA-DR and CD117.1-3 Co-
expression of lymphoid-associated antigens is some-
times seen but does not preclude diagnosis.4
The incidence of abnormal karyotypes is more fre-
quent in AML-M0 (71 to 81%) than in other sub-
types.2,3,5 Complex aberrant karyotypes are detected in
approximately 20% of AML-M0 cases, and unbalanced
chromosomal changes involving -5/del(5q),-7/del(7q),
+8, +11 and +13 are the most frequent.2,3,5 Nevertheless,
unlike for other AML subtypes, no characteristic
translocation has been described for AML-M0.
The most frequently recurring molecular alterations
observed in AML-M0 are mutations in RUNX1 (alias
AML1).6 These are mainly biallelic or dominant-nega-
tive point mutations, other than translocations, and are
detected in 15 to 35% of cases.6 RUNX1 is a transcrip-
tion factor essential for hematopoiesis that binds DNA
through its Runt domain.7 RUNX1 is described as both
a tumor suppressor gene (TSG), as in AML-M0,8 and as
an oncogene, as it is frequently involved in chromoso-
mal translocations in various hematologic malignan-
cies.9 Other genes found to be mutated in AML-M0
include FLT3, RAS and PTPN11.10-14 However, these
mutations are considered to be, rather than surrogates,
collaborating abnormalities with mutations in transcrip-
tion factors such as RUNX1.15
In this study we aimed to identify new molecular
alterations that could explain the etiology of AML-M0.
Together with cytogenetic and immunophenotypic
analyses, we analyzed a unique cohort of 52 AML-M0
samples by whole genome single nucleotide polymor-
phism (SNP) screening to reveal regions of loss or gain
that could contain putative TSG or oncogenes. We also
performed extensive mutation analysis in genes known
to be mutated frequently in AML. 
Design and methods
Patients’ material
This study was performed with archived material
from diagnostic cryo-preserved bone marrow aspirates
from 52 patients (numbered from 1 to 9 and 18 to 60),
classified morphologically and immunophenotypically
as having AML-M0 (presented in Table 1 and in an Online
Supplementary file). Material was collected from the
medical centers at the Robert-Rössle-Clinic, Charité
Berlin, Germany; University of Leiden, the Netherlands;
University of Groningen, the Netherlands; Erasmus
University, Rotterdam, the Netherlands; and University
of Vienna, Austria. All samples were handled in a coded
fashion and research was conducted following the med-
ical ethical guidelines of the national organization of sci-
entific societies (FEDERA; Code for Proper Secondary Use
of Human Tissue in The Netherlands). Pure tumor cell pop-
ulations were sorted by flow cytometry from mononu-
clear cells isolated from bone marrow or peripheral
blood at the time of diagnosis.8 T cells from each sam-
ple (with the exception of those from patients 38 and
49) were expanded using previously described condi-
tions as a source for control material.8,16 DNA was iso-
lated from the sorted tumor cells and T cells using the
QIAamp DNA Blood Mini Kit (Qiagen, Hilden,
Germany). RNA was isolated from the mononuclear cell
fraction using the QIAamp RNA Blood Mini Kit
(Qiagen). cDNA was prepared using SuperScript® First-
Strand Synthesis System for reverse transcriptase poly-
merase chain reaction (RT-PCR) (Invitrogen, Breda, the
Netherlands).
Karyotyping
Cytogenetic analysis was performed on GTG-banded
chromosomes and the karyotype was assigned accord-
ing to the criteria of the International System for
Human Cytogenetic Nomenclature (ISCN).17 A complex
aberrant karyotype is defined in this study by at least
five abnormalities. 
Single nucleotide polymorphism analyses
SNP analysis was performed using the GeneChip
Mapping 10k 2.0 array (Affymetrix, Santa Clara, CA,
USA) following the manufacturer’s instructions. Briefly,
250 ng of total genomic DNA was digested with XbaI
restriction enzyme and ligated to a universal adapter.
The ligated fragments were then PCR-amplified using
primers complementary to the universal adapters. PCR
products were purified, fragmented by DNase I, labeled
with biotinylated dATP and hybridized to the array.
The arrays were scanned using a GeneChip Scanner
(Affymetrix). Affymetrix GeneChip 5.0 genotyping
software was used to examine the SNP hybridization
patterns and to make SNP calls. The resulting data were
analyzed with the dChip software package.18
Mutation screening
RUNX1, FLT3 internal tandem duplications (ITD) and
FLT3 D835 mutation screening was performed as previ-
ously described.8,19 KIT D816V mutations (exon 17)
were screened using the HinfI restriction assay.20 All
patients were screened for these mutations.
Melting curve analysis was performed for all patients
to detect mutations in NRAS (codons 12/13 and 61),
KRAS (codon 61), JAK2 (codon 617), PTPN11 (exons 3
and 13), PTPN6 (exons 3 and 13) and SPI1 (exons 1 to
4). The above mentioned regions were amplified in
reactions containing LCGreen PLUS (Idaho Technology,
Salt Lake City, UT, USA) using the primers and condi-
tions described in the Online Supplementary Appendix.
Subsequently, melting curves of the PCR products were
generated in a LightScanner HR 96 (Idaho Technology).
Aberrant melting curves were subjected to DNA
sequencing to confirm mutations, as previously
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described.8 Standard PCR techniques were used to
amplify RUNX1 (exons 6 to 8), NRAS (codon 61),
CEBPA, CEBPD, SPI1 (exon 5), TET2, PURA, PILRA,
PILRB from genomic DNA and RUNX1, CSF2RA and
IL3RA from cDNA (Online Supplementary Appendix).
Subsequent DNA sequencing was performed as previ-
ously described.8 CEBPA and CEBPD sequencing reac-
tions included, in addition to standard reagents, 1.6 M of
betaine (Sigma-Aldrich, Saint-Louis, MO, USA). 
NPM1 exon 12 and CEBPB mutations were studied by
fragment analysis. After amplification (the conditions
and primers are presented in the Online Supplementary
Appendix), the PCR products were analyzed on a 3730
DNA Analyzer (Applied Biosystems, Foster City, CA,
USA) with GeneScan 500 ROX (Applied Biosystems) as
a size standard. Detected mutations were confirmed by
sequencing.8
The tumor specificity of mutations detected in
genomic DNA of AML tumor cells was confirmed by
sequencing the respective control DNA (expanded T
cells) for the absence of mutations. 
Results
Minimally differentiated acute myeloid leukemia
shows karyotype heterogeneity
The cohort of 52 patients was not selected for any cell-
biological feature other than the diagnosis of AML-M0.
The cohort had a median age of 61 years and consisted
of 47 de novo cases, 1 therapy-related case and 4 cases of
secondary leukemia (Table 1). 
Karyotypes were available for 49 cases (Table 1). Six
(12%) cases had complex aberrant karyotypes, 14 (29 %)
cases were normal and 17 (35%) cases were associated
with a single abnormality. The remaining 12 cases car-
ried two or three chromosomal abnormalities. The pre-
dominant single abnormalities were trisomy 13, trisomy
8 and monosomy 7. Overall the most frequent abnor-
malities detected were del(5q), trisomies 8 and 13 and
monosomy 7/ del(7q) (Table 3). 
We also detected several chromosomal abnormalities
that might involve known transcription factors, includ-
ing the del(16)(q22) (patient 42), frequently associated
with CBFB, the inv(3)(q21q26) and t(2;3)(p23;q27)
(patients 51 and 4), associated with EVI1, and the previ-
ously reported translocations involving ETV6 in cases 2,
9 and 43 (Table 1).21
Single nucleotide polymorphism array analysis
revealed several potential new regions involved in
minimally differentiated acute myeloid leukemia
We compared DNA isolated from flow-sorted
leukemic cells to control DNA of the same patients using
the Affymetrix GeneChip 10K mapping array. Loss of
genetic information, detected as loss of heterozygosity
(LOH) and/or copy number changes, was found in sev-
eral chromosomes (Tables 1 and 2). Twenty-three
regions were found to be affected in 37 AML-M0
patients. Most patients had losses or gains additional to
those found by karyotype analysis. Interestingly, of the
14 patients with a normal diploid karyotype, nine dis-
played LOH on at least one chromosome (Table 1). 
LOH was most frequently observed in chromosomes
21, 17, 7 and 5. As regards chromosome 21, copy neutral
LOH (also known as uniparental disomy [UPD] or [par-
tial] isodisomy) was found in 14 cases and a hemizygous
deletion in 3 cases (Figure 1A). Homozygous deletions of
the region on chromosome 21 harboring the tumor sup-
pressor gene RUNX1 were detected in three of the 17
cases with LOH (Table 2, Figure 1A). LOH in chromo-
somes 5 (9 patients) and 7 (9 patients), in contrast to that
in chromosome 21, was mainly due to deletions. In
chromosome 17 the minimal regions of overlap in LOH
between the patients comprised two separate regions,
one including TP53 and the other NF1 (Table 2, Figure
1B). LOH was also detected in chromosomes 3 (5
patients), chromosome 4 (4 patients) and chromosome
12 (4 patients). LOH in chromosome 12 resulted from a
hemizygous deletion that included the ETV6 locus, as
previously reported.21 Microdeletions (smaller than 2
Mb) were present in three patients, affecting chromo-
somes 3, 4, 8 and 11 (Table 2). The remaining examples
of LOH were restricted to a limited number of patients
(Table 2). In addition, two cases showed gain of genom-
ic regions in chromosomes 3 and X/Y (Table 2). 
Mutation analysis of candidate genes did not reveal
new targets
Following the results of the SNP analysis we screened
several candidate genes, located within the minimal
common regions of LOH or gain, for mutations. Genes
were selected based on their potential relevance for
leukemia, and included PURA, PILRA, PILRB, TET2 and
CEBPD for regions of LOH, and IL3RA and CSF2RA for
a region of amplification near the pseudo-autosomal
region of chromosomes X and Y (Table 2). In most cases,
mutation screening was restricted to the samples show-
ing LOH or copy number gain (Online Supplementary
Table S2). No mutations were detected in any of these
candidate genes. However, CSF2RA and IL3RA, which
are involved in hematopoietic development,22 were
shown to be highly up-regulated by gene expression
microarray analysis (data not shown).
RUNX1 mutations in minimally differentiated acute
myeloid leukemia are not restricted to the RUNX1
runt domain
Mutations in RUNX1 were detected in 18 patients
(35%) (Table 1 and Online Supplementary Table S1). In
concordance with the SNP analysis, 13 of these muta-
tions were homozygous/biallelic (Table 1 and Figure
1A). Patient 38 had a homozygous mutation but without
detectable LOH (Table 1). The most common RUNX1
mutations found in exons 3, 4 and 5 were base substitu-
tions in or near to the DNA binding runt domain (Table
1). We also detected four insertions that resulted in trun-
cated proteins as well as one insertion/duplication and
one deletion. In addition, exons 6, 7 and 8 of RUNX1
were sequenced in samples for which a mutation was
expected based on the LOH results and other analyses.
In two samples (from patients 26 and 41) we found a
frame shift mutation. In only one patient (patient 52)
with UPD (Figure 1A), a RUNX1 mutation remained
LOH and mutations in AML-M0
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Table 1. Molecular, clinical, immunological and cytogenetic features of the patients.
Patient Age AML-M0 Karyotypej Other Mutations in Other Inferred Immunophenotype (%) of cells
status (years) chromosomesj transcription factorsa mutationsa genes CD34 CD33 MPO TdT
1b,d 65 46,XX,i(17)(q10), 12 JAK2 V617F; ETV6e; TP53e 71 71 0,5
del(20)(?) PTPN11 E76K
2b,d 67 Secondary 47,XX,t(4;12) 4, 22 ETV6 t(4;12)d NRAS Q61H; RUNX1e 95 5 0,5 0,4
(PV) (q12;p13),-21, +2r(21) PTPN11 D61H
3b 43 46,XX 86 50 79
4b 68 46,XY,t(2;3)(p23;q27) 3, 4 EVI1/MDS t(2;3)g 50 44 0
+ hemizygous dele
5b 61 Complex Complex PTPN11 D61Y TP53e 58 67 0
6b,d 37 46,XY 17 ETV6 [S107fs]+[V345_Y346insR]d NF1e 56 70 10 3
7b,c 68 47,XY, +13, i(17)(q10) 1, 21 RUNX1 W79C FLT3f; TP53e 74 3 83
8b 68 46,XX 5, 17 NF1e 0 84 12
9b,d 47 Secondary Complex Complex KRAS G12D ETV6e 77 74 1 1
18b 83 45,XY,-7, del20(q1?2) 21 RUNX1 del 91 35 87
19b 68 46,XY 4, 21 RUNX1 del FLT3 ITD 75 10 81
20 73 47,XY,+8 3 97 86 6 10
21d 59 46,XY 17 ETV6 R360Xd 95 5 1 2
22 77 47,XY,+9 93 42 2 95
23 62 Secondary (PV) 46,XY 9 JAK2 V617F 60 77 2 6
24 5 45,XY,-7 21 RUNX1 R139Q NRAS G13D 89 70 74 58
25 59 Complex Complex RUNX1e; TP53e; NF1e 91 69 1 7
26 65 47,XY,+8 7, 21 RUNX1 A297fs 76 39 5 58
27c 58 n.d. 21 RUNX1 R80H FLT3f 86 18 3 76
28 69 Secondary (MDS) 47,XY,+8 RUNX1 D48Y JAK2 V167F 88 35 1 13
29 45 46,XX,del(7)(q22) 3 FLT3 ITD 76 72 12 22
30c 55 47,XY,+13 21 RUNX1 W79C PTPN11 G60V FLT3f 89 21 4 27
31c 68 96,XXYY,+13,+13,der(17) RUNX1 A115fs FLT3f; TP53e 92 56 4 45
t(16;17)(p11;p11)x2,+19,+19
32c 64 47,XY,+13 21 RUNX1 D171V FLT3f 91 5 3 68
33 31 Complex Complex RUNX1e; TP53e 71 71 8 1
34 22 46,XY,t(11;19)(q13;p13) FLT3 ITD 96 98 6 0
35 35 46,XY 8 CEBPA [D69fs (+) K313dup] NRAS G13D CEBPDe 94 95 96 16
36c 65 47,XY,+13 RUNX1 R142fs FLT3f 94 11 0 83
37 74 Therapy related Complex Complex RUNX1 M106fs 82 33 12 77
38 64 n.d. RUNX1 [L55fs (+) FLT3 ITD 45 68 8 0
V128_A129insEY_E111_V128dup]
39 74 47,XX,+14 5, 7, 21 RUNX1 del 89 54 4 41
40 49 46,XY 56 8 3 0
41 51 46,XY RUNX1 R319fs 78 67 44
42 57 47,XX,del(16)(q22), +21 FLT3 D835V CBFB del(16)(q22)g 70 18 3 1
43d 64 46,XY, t(4;12)(q12;p13) ETV6 t(4;12)d 71 51 8 81
44 60 45,XY,-7 5 PTPN11 E76V 60 20 0
45d 29 n.d. Complex ETV6e, NF1e 90 55
46c 81 47,XX,+13,16qh+c FLT3f 90 0 2
47 75 46,XX 21 RUNX1 K83N 85 0 0
48 71 46,XY 95 2 6
49 78 47,XX,+8 FLT3 ITD 95 0 1
50 86 46,XX,t(9;11)(q34;p11.2) 4, 11, 19 75 15 2
51 33 46,XY,inv(3)(q21q26) FLT3 ITD EVI1 inv(3)(q21q26)g 95 60 1
52 24 46,XX,hexaploid 21 FLT3 ITD RUNX1h 95 1 0
53c 86 46,XY,der(13)t(13;21) 21 RUNX1 del FLT3f 70 32 8
(q32~34;q22),+der(13),-21
54 47 Complex complex NF1e 97 84 0
55 62 46,XY 7, 21 RUNX1 V105fs 88 46 0 49
56 49 49,X,idic(Y)(q12)x3 X/Y NRAS Q61R 93 94 1 0,1
57 57 50,X,idic(Y)(q12)x4 2 80 0,1
58d 50 47,XY,idic(21)(q10), 19 ETV6 F103fsd FLT3 ITD 91 83 1
+add(21)(p1?1)
59 40 46,XY NPM1 W288fs; KRAS G12D 1 87 2 1
60 59 46,XX 5 FLT3 ITD; PTPN11 E76Q 80 94 4 1
amutations in bold are homozygous; bpublished in Silva et al. (2003)8; cpublished in Silva et al.,(2007)19; dpublished in Silva et al. (2008)21; ehemizygous locus loss detected by SNP analysis;
f:FLT3 over expression associated with trisomy 13 (Silva et al., 2007)19; ginferred from cytogenetic data; hinferred from UPD; iin case of multiple karyotypes the one confirmed by copy number
analysis is shown; jchromosomes with LOH or copy number changes detected by SNP analysis only, see table 2 for complete information; n.d. : not done; PV : polycythemia vera; MDS: myelodys-
plastic syndrome.
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undetected. In addition to patients 18, 39 and 53 (Figure
1A, Table 2), RUNX1 appeared to be homozygously
deleted in patient 19.8
Mutations in other acute myeloid
leukemia- associated transcription factors are
infrequent
We screened all patients for mutations in CEBPA,
CEBPB and SPI1. We found biallelic CEBPA mutations in
patient 35 (Table 1 and Online Supplementary Table S1).
No mutations were detected in CEBPB or SPI1. All
patients were also screened for exon 12 insertions in
NPM1. Patient 59 showed a four nucleotide insertion
(Table 1 and Online Supplementary Table S1). This patient
did not express CD34 and had a normal karyotype, as
reported in other cases with NPM1 mutation.23
RAS-related genes are frequently mutated in
minimally differentiated acute myeloid leukemia
We detected 25 mutations in 22 patients (42%) in
genes related to the RAS and JAK signaling pathways
(Tables 1 and 3; Online Supplementary Table S1). FLT3
mutations were the most frequent mutations, i.e., nine
FLT3 ITD and one FLT3 D835. Activating mutations in
RAS genes were present in six patients (11.5%), two in
KRAS and four in NRAS. PTPN11 mutations were
observed in 6 patients (11.5 %). Activating mutations in
codon 617 of JAK2 were found in three patients, two of
whom had a previous history of hematopoietic disor-
ders. In patient 23, the JAK2 mutation was homozygous,
in line with UPD detected in chromosome 9 (Table 1).
PTPN11 mutations coexisted with RAS, FLT3 and JAK2
mutations in one case each (Table 1). 
We did not find any mutations in exons 3 or 13 of
PTPN6, a PTPN11-related gene, or in KIT. A summary of
the results is presented in Table 3 and detailed informa-
tion on the detected mutations is given in Online
Supplementary Table S1.
RUNX1 mutations are associated with terminal
deoxynucleotidyl transferase expression in minimally
differentiated acute myeloid leukemia
Data on protein expression of TdT were available for
40 cases (Table 1). Twenty-two (55%) cases demonstrat-
ed high TdT expression (>10% of cells). Notably, we
found a strong association between high protein expres-
Table 2. Summary of minimal common regions of chromosomal losses, gains and uniparental disomy detected by LOH and copy number analyses. 
Chrom. region Aberrationd Patient(s)e Proximal SNP Distal SNP Size (Mb) Candidate genes
1 p32.2-pter (36.33) UPD 7 rs1926910 telomere ~56.041
3q25.33-q26.2 UPD (2), Loss (2) 5, 20, 29, 45 rs958985 rs721128 10.088 IL12A, KPNA4, 
NMD3, PDCD10
3q26.2 Loss 4 rs1488106 rs1920116 0.721 EVI1, MDS
3q26.2-qter (29) Gain 29 rs974944 telomere ~29.135
4q24 UPD (2), Loss (1) 2, 4, 19 rs1528382 rs1374530 1.314a TET2b
4q31.22-qter (35.2) UPD 4, 19, 50 rs720485 telomere ~45.271
5q31.2-q32 UPD (1), Loss (8) 5, 8, 9, 25, 33, rs2351463 rs724603 7.435 PURAb
37, 39, 44, 60
7q32.1-qter (36.3) UPD (2), Loss (7) 5, 18, 24, 26, rs721691 telomere ~29.980 CDC26, 
29, 39, 44, 45, 55 FAM40B
8qcen(11.1)-q11.21 Loss 35 centromere rs1384217 ~2a CEBPDb, MCM4
9p21.2-pter(24.3) UPD 23 rs721672 telomere ~25.733 JAK2b
11q12.2-q13.2 UPD, Loss 25, 50 rs1593480 rs1938684 9.168
11q14.1-q14.2 UPD, Loss 25, 50 rs62388 rs1378879 1.533
12p13.31-p13.2 Loss 1, 9, 33, 45 rs747726 rs252028 3.257 ETV6b,f
16q21-q23.1 Loss 42 rs588037 rs725710 11.489 CBFB
17p13.1-p13.2 Loss 1, 5, 7, 25, 31, 33 rs1379867 rs724809 5 TP53
17q11.2 Loss 6, 8, 25, 45, 54 rs719601 rs1394385 2.958a NF1
17q21.31-qter(q25.3) UPD 21, 45, 54 rs1981998 telomere ~35
19q12-qter(13.43) UPD 50 rs9304866 telomere ~30
19p13.2pter(23.3) UPD 58 rs2009518 telomere ~9.661
20q11.23-q13.2 Loss 1, 18, 33 rs910760 rs2208006 14.207
21q22.12 UPD (13), Loss (4) 2, 7, 18, 19, 24, rs2409561 rs1573304 1.042c RUNX1b,c
25, 26, 27, 30, 
32, 33, 37, 39, 
47, 52, 53, 55
22q11.21-qter(q13.33) UPD 2, 9, 25 rs878825 telomere ~28.609
X/Yp22.33 Gain 56 rs9334 telomere 2.832 CSF2RAb, IL3RAb
Chromosomal regions presented,proximal SNP,distal SNP and size refer to the minimally common regions between patients.Trisomies or monosomies were not considered for this
table.Patients showing complex aberrant karyotypes were not used to define minimally common regions with exception of 12p13 and 17p13. aconfirmed by MLPA analysis; bgene
screened for mutations; cdefined by homozygous deletions; dUPD equals copy-neutral LOH,Loss equals hemizygous deletion; epatients with UPD in bold; fpublished in Silva et
al.,(2008)21.
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Figure 1. Single nucleotide polymorphism analysis of patients showing chromosome 17 or 21 abnormalities. (A) LOH in chromosome
21 was detected in 17 patients. LOH was related to a hemizygous deletion in four patients (2, 25, 33, 53) and UPD (copy neutral) in
13, as can be seen by the copy number call. Homozygous deletions were detected in three patients (18, 39, 53) and affected the RUNX1
locus. Chromosome representation, cytoband and gene distribution (overview) are at the left side of the panel. Candidate genes are
underlined. The left heat map shows inferred LOH calls based on a hidden Markov model considering haplotype (using the paired nor-
mal). Each column represents one patient’s result. Each box represents the combined call for one or more SNP between tumor sample
and respective control (T cells). The right heat map represents chromosome copy number inferred using the paired normal as reference
and a median smoothing. Dark gray boxes represent two copies, light gray boxes represent one copy (deletion) and black boxes repre-
sent three copies for each chromosome locus. Homozygous deletions are represented by striped boxes (see copy number heat map).
(B) LOH at chromosome 17 was detected in 11 patients. Two main regions of LOH were detected: one including the TP53 locus, shared
by patients 1, 5, 7, 25, 31, and 33, the other including the NF1 locus, in patients 6, 8, 25, 45 and 54. In addition three patients showed
extensive LOH of the q arm of chromosome 17. Legend as in panel (a).
A
B
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sion of TdT and presence of a RUNX1 mutation (one-
sided Fisher’s exact test; using a 10 % expression cut-off
p=0.00002 or a 20 % cut-off p=0.00001). The only
exceptions to this association were patients 28 and 38
who, although carrying RUNX1 mutations, showed no
or low expression of TdT, and patients 3, 22 and 43 who
showed high TdT expression without having RUNX1
mutation (Table 1). 
Discussion
In the last years, the approach to the classification of
AML has shifted from a morphological to a molecular
basis. Although the cohort of patients studied here was
selected based on morphological criteria, recent results
using gene expression profiling have shown that AML-
M0 patients cluster together as a separate group of AML-
M0.24 In the present study we aimed to identify TSG and
oncogenes that might contribute to the AML-M0 pheno-
type. Whole genome SNP analysis revealed various new
regions of LOH containing known and candidate TSG.
Conversely, chromosomal gains were rare. Many of the
LOH regions described here could not have been found
by standard cytogenetic techniques as they were UPD
(Table 1 and 2). Two LOH regions containing known
TSG were on chromosome 17. LOH at 17p13.1 (TP53)
was clearly independent from that at 17q11.2 (NF1).
This result confirms similar findings in AML.25,26
However, our results suggest that both regions have
equal importance in AML-M0, since the number of
occurrences for each region is comparable. TP53 has an
important role in the maintenance of chromosomal sta-
bility and its deletion has been linked to AML with com-
plex karyotype.26 In concordance, three AML-M0
patients with TP53 loss also had complex karyotypes.
NF1 is involved in negative regulation of the RAS path-
way (see below) and is found to be mutated in patients
with hematopoietic disorders.27 Interestingly, a third
region of LOH was detected in chromosome 17 imply-
ing that another TSG is present at 17q (Table 2). 
In a number of minimal LOH regions without known
TSG, we screened several candidate genes or transcripts
for mutations, including CEBPD at chromosome 8, TET2
at chromosome 4, and others at chromosomes 3, 5 and
7 (Table 2). Candidate genes were selected based on the
likelihood of them having a role in AML-M0 or, in the
case of the region containing TET2, because it was
described as a microdeletion in four patients.28 No muta-
tions were found in any of the candidate genes.
However, for some of the LOH regions detected, hem-
izygous deletions may already be sufficient for the neo-
plastic process, without requiring a mutation in the
other allele.29 In fact, several reports suggest that hap-
loinsufficiency of one or more genes, especially in chro-
mosome 5 and 7, contributes to AML.26,30,31 Of note,
some of the areas of LOH detected by us, in particular
the ones with UPD, were too large to be screened effi-
ciently for TSG. Importantly, genome wide SNP analysis
also showed that the genomic region on chromosome 21
containing the TSG RUNX1 is the most frequently
affected region in AML-M0 (Figure 1A). The complete
loss of RUNX1 or biallelic RUNX1 mutations observed
in the majority of patients with UPD in chromosome 21
was in line with mitotic recombination being the mech-
anism of homozygosity.8 On the other hand, deletion of
one RUNX1 allele appears to co-exist with complex pat-
terns of LOH (Table 1 and 2). In all, we detected 18 cases
(35 %) with RUNX1 mutation of which 15 were biallel-
ic. This number is higher than in previous studies.6 Most
of the mutations affected the runt domain and are con-
sidered to result in loss of DNA binding ability.32,33
Interestingly, two of the RUNX1 mutations were found
in the transactivation domain. To our knowledge, C-ter-
minal RUNX1 mutations have not been reported in
AML-M0, although a few cases in other AML subtypes
have been reported and they are frequent in myelodys-
plastic syndrome.6,34,35 
As over 60% of the AML-M0 cases retained normal
RUNX1, we screened the cohort for mutations in other
hematopoietic transcription factors frequently implicat-
ed in AML. Mutations in CEBPA, CEBPB and NPM1
were rare, showing that AML-M0 is largely unrelated to
these provisional World Health Organization (WHO)
subgroups.36 In fact, only a few patients (patients 35, 51
and 59) classified in this study as having FAB AML-M0
would not be considered to be part of the WHO sub-
group with minimally differentiated leukemia. Contrary
to a study showing a high (23%) frequency of mutation
in AML-M0,37 we and others found no mutations in
SPI1.13,38 It seems that mutations of these transcription
factors are not an alternative to RUNX1 mutation in
AML-M0. However, as we previously reported, ETV6
mutations are infrequent alternatives to RUNX1 muta-
tion in this cohort.21
FLT3, RAS and PTPN11 are genes of the RAS pathway
and mutations in these genes heve been reported to col-
laborate with RUNX1 mutations in the pathogenesis of
AML by providing a proliferative advantage to the
cells.10-14 We detected a higher frequency of RAS (12%)
and PTPN11 (12%) mutations in AML-M0 than in previ-
Table 3. Summary of molecular findings and main cytogenetic
abnormalities.
Cases Percentage 
of total
Confirmed mutations
RUNX1 20 39
ETV6a 5 10
CEBPA 1 2
FLT3 10 19
RAS 6 12
PTPN11 6 12
JAK2 3 6
NPM1 1 2
Main cytogenetic abnormalities
Del(5q) 8 15
-7/del(7q) 7 14
+8 5 10
+13 8 15
a :published in Silva et al., (2008)21.
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ous studies (Table 3).11-13 Mutation frequencies for FLT3
(19%) were in accordance with other published data for
AML and AML-M0.10,39-41 It is possible that the number of
cases involving these genes is even higher, since we
sequenced only mutational hotspots. Interestingly,
mutations in FLT3, RAS and PTPN11 were absent in
patients showing a deletion of the NF1 region. This
result is in line with the view that deletion of NF1 might
be an alternative to activation of the RAS signaling path-
way in AML-M0. Finally, we detected three cases with
mutation in JAK2, another gene involved in cell prolifer-
ation (Table 3). JAK2 mutations occur frequently in
myeloproliferative disorders and less commonly in
myelodysplastic syndrome and de novo AML.42,43 Though
two of our cases had a previous history of hematopoiet-
ic disorders, this result could indicate some relation
between AML-M0 and JAK2 mutation (Table 1). 
Contrary to previous findings, mutation of RAS path-
way-related genes did not correlate with RUNX1 muta-
tion.14,44 We also did not find a positive association
between -7/del(7q) and RUNX1 mutation or a negative
one between del(5q) and RUNX1 mutation as previous-
ly reported in myelodysplastic syndrome,44 although a
similar trend was noticeable. In fact, the only mutation
associated with mutations in RUNX1 was trisomy 13, as
observed by us and others.19,34 Trisomy 13 is also corre-
lated with higher FLT3 expression and is probably
another factor contributing to proliferative advantage in
AML-M0. 
TdT expression is a common characteristic of CD34+
immature AML and is associated with a poor progno-
sis.45 Remarkably, RUNX1 mutation and TdT expression
were strongly correlated. TDT encodes a DNA poly-
merase normally expressed in pre-B and pre-T lympho-
cytes during early differentiation.46 Recently, we found,
by gene expression profiling, that AML-M0 RUNX1
mutants showed a characteristic B-lymphocyte signa-
ture, which could explain this correlation.24 TdT expres-
sion in leukemia is frequently assessed by immunophe-
notyping. Thus screening for RUNX1 mutations in
AML-M0 at diagnosis might become possible by meas-
uring TdT. 
In conclusion, whole genome SNP analysis confirmed
our previous findings that events leading to partial UPD
are a major cause of mutation homozygosity in AML-
M0.8 In fact, recent reports show that UPD is common in
AML, myelodysplastic syndrome and myeloprolifera-
tive disease,47-50 suggesting that this is a general mecha-
nism leading to loss of TSG activity in hematologic dis-
orders. The observed heterogeneity in chromosomal
losses in AML-M0 without RUNX1 mutation suggests
that not one but several genes may be alternatives to
RUNX1 mutation. Conversely, mutations related to cell
proliferation, though genetically diverse, affect mainly
the RAS pathway. Combining trisomy 13 and hemizy-
gous loss of NF1 with the mutations found in FLT3,
NRAS, JAK2 and PTPN11, we detected a strikingly high
frequency (63%) of cell proliferation-related mutations.
Importantly, we showed a strong association between
TdT expression and RUNX1 mutation suggesting that
TdT expression may serve as a surrogate marker for
RUNX1 mutation in AML-M0. 
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